Leaps by Bayer

Founded 2015

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 29
Average round size
info
The average size of a deal this fund participated in
$52M
Portfolio companies 28
Rounds per year 4.83
Lead investments 8
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.03
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Agriculture
  • Medical
  • Therapeutics
Summary

Leaps by Bayer appeared to be the Corporate Investor, which was created in 2015. The main department of described Corporate Investor is located in the Leverkusen. The company was established in Europe in Germany.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Leaps by Bayer, startups are often financed by Longwood Founders Fund, Ipsen, Agent Capital. The meaningful sponsors for the fund in investment in the same round are Longwood Founders Fund, Ipsen, Agent Capital. In the next rounds fund is usually obtained by Longwood Founders Fund, Ipsen, Agent Capital.

Besides, a startup needs to be aged 1 and less years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Century Therapeutics, Pyxis Oncology, Pyxis Oncology Among the most popular fund investment industries, there are Therapeutics, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups.

The high activity for fund was in 2019. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. Speaking about the real fund results, this Corporate Investor is 47 percentage points more often commits exit comparing to other organizations.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

MedArrive

Health Care
Hospital
Medical
Medical Device
Virtual Workforce
$25M17 Nov 2021 New York, New York, United States

Sound Agriculture

Agriculture
Biotechnology
Farming
$45M19 Aug 2021 California, United States

Transcarent

Family
Health Care
Information Technology
$58M10 Jun 2021 San Francisco, California, United States

Kojin Therapeutics

Biopharma
Biotechnology
Life Science
Medical
$60M09 Jun 2021 Cambridge, Massachusetts, United States

Ada Health

Apps
Artificial Intelligence
Health Care
Medical
mHealth
$87M27 May 2021 Berlin, Berlin, Germany

Huma

Big Data
Biotechnology
Health Care
Information Technology
Insurance
Management Information Systems
mHealth
Pharmaceutical
Sports
Wearables
Wellness
$130M11 May 2021 London, England, United Kingdom

Edifice Health

Biotechnology
Health Care
Wellness
$12M22 Apr 2021 California, United States

Amfora

Agriculture
Biotechnology
Health Care
$6M23 Mar 2021 San Francisco, California, United States

Biotechnology
Health Care
Health Diagnostics
Therapeutics
$160M03 Mar 2021 Philadelphia, Pennsylvania, United States
News
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

Zerigo Health Raises $43 Million in Series B Funding to Drive Adoption of the Industry’s Only Connected Light Therapy Solution to Treat Chronic Skin Conditions

– Zerigo Health announced a $43m Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer.
– The round also included participation by existing investors including SV Health Investors, H.I.G. Capital, and Bluestem Capital.
– This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema.
– Glen Tullman, Managing Partner of 7wireVentures, former Founder and CEO of Livongo, and Chief Executive Officer of Transcarent, will join as Executive Chairman of the company’s Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Leaps by Bayer?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: